Results 131 to 140 of about 13,147 (207)

Using cocaine and apomorphine self-administration in rats to measure the pharmacokinetics of competitive dopamine receptor antagonists administered by different routes. [PDF]

Sci Rep
Song HJ, Desai JN, Norman MK, Norman AB.
europepmc   +1 more source

Dapagliflozin ameliorates motor deficits in a Parkinson's disease model induced by 6-OHDA: An integrative in vivo and in silico approach from α-synuclein/A2AAR/TH/TNF-α to APAF-1/caspase-3 modulation. [PDF]

Inflammopharmacology
Sezen S, Burul F, Okkay U, Karadayı M, Ozkaraca M, Bayram C, Gülşahin Y, Ferah Okkay I, Gulluce M.   +8 more
europepmc   +1 more source

Structure-guided discovery of non-catechol dopamine D1 receptor ligands with biased agonism and antagonism. [PDF]

J Biol Chem
Zhou Y, Wetsel WC, Kahsai AW, Olson SH, Barak LS.   +4 more
europepmc   +1 more source

Apomorphine-induced disruption of paced mating behavior in female rats is attenuated by eticlopride, a D2 receptor antagonist, but not SCH 23390, a D1 receptor antagonist. [PDF]

Horm Behav
Kong AAH, Beasley TR, Munson HJF, Meerts SH.   +3 more
europepmc   +1 more source

[Continuous Subcutaneous Apomorphine Infusion Therapy: Economic Impact in Spain]. [PDF]

Rev Neurol
Micolta-Córdoba L, Castro-Ramirez JP, Reyes-Ortiz C.   +2 more
europepmc   +1 more source

pH-Sensitive Dextrin-Based Nanosponges Crosslinked with Pyromellitic Dianhydride and Citric Acid: Swelling, Rheological Behavior, Mucoadhesion, and In Vitro Drug Release. [PDF]

Gels
Hoti G, Er-Rahmani S, Gatti A, Hussein I, Argenziano M, Cavalli R, Anceschi A, Matencio A, Trotta F, Caldera F.   +9 more
europepmc   +1 more source

Isotopically enriched ⁶⁴ZN-aspartate attenuates systemic inflammation and gut dysbiosis in an LPS-induced rat model of Parkinson's disease. [PDF]

Sci Rep
Temnik M, Rudyk M, Balakin A, Gurin S, Dovbynchuk T, Byshovets R, Dzubenko N, Dovhyi R, Serhiichuk T, Tolstanova G, Skivka L.   +10 more
europepmc   +1 more source

Subcutaneous Foslevodopa as Rescue Therapy for Abrupt Interruption of Oral Dopaminergic Treatment in Parkinson's Disease. [PDF]

Mov Disord Clin Pract
Ory-Magne F, Houeto JL, Fabbri M.
europepmc   +1 more source

Advanced Therapeutics in Parkinson's Disease: What's New? [PDF]

Curr Neurol Neurosci Rep
Monje MHG, Karl JA, Cooper CS, Yomtoob J, Deliz J, Morse LA, Shetty N, Verhagen Metman L.   +7 more
europepmc   +1 more source